IP Library Granted Patent US 9,833,412
Granted Patent B2
US 9,833,412 · App. 14/188,150 · Granted Dec 5, 2017

Triple combination release multi-layered tablet

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,833,412
App. No.
14/188,150
Granted
Dec 5, 2017
Kind
B2
Abstract

This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet ( 1 ) comprising two external drug-containing layers ( 2 and 3 ) in stacked arrangement with respect to and on opposite sides of an oral dosage form ( 4 ) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.

Claims (23)

1. A combination release tablet comprising:

a) a drug-containing rapid release first compressed composition comprising at least one drug, a first filler and a second filler;

b) a drug-containing extended release second compressed composition comprising at least one drug, release rate modifier, the first filler and the second filler; and

c) a film-coated extended release intermediate drug-containing composition enclosed between the first compressed composition and the second compressed composition and comprising a drug-containing core surrounded by a film coating; wherein the first compressed composition and second compressed composition oppose one another, are in direct contact with each other, and are in direct contact with, in stacked arrangement with respect to, and disposed on opposite faces or surfaces of the intermediate drug-containing composition, wherein the preformed and film-coated extended release intermediate drug-containing composition is an osmotic device comprising a core surrounded by a membrane having a preformed passageway through it, wherein the preformed passageway is plugged by the first or second compressed composition and initial release of drug from the core after administration is delayed, whereby the tablet provides three different active agent release profiles.

2. The tablet of claim 1 , wherein the first compressed composition comprises binder.

3. The tablet of claim 2 , wherein the first compressed composition further comprises disintegrant.

4. The tablet of claim 1 , wherein the first filler and the second filler are selected from the group consisting of: dibasic calcium phosphate, kaolin, lactose, sucrose, mannitol, microcrystalline cellulose, powdered cellulose, precipitated calcium carbonate, sorbitol, and starch.

5. The tablet of claim 4 , wherein the release rate modifier is selected from the group consisting of water-soluble natural polymers, water-soluble semi-synthetic polymers and water-soluble synthetic polymers.

6. The tablet of claim 4 , wherein the release rate modifier is selected from the group consisting of: a) natural polymer selected from the group consisting of polysaccharide and polypeptide; b) semi-synthetic polymer selected from the group consisting of cellulose derivatives; and c) synthetic polymer selected from the group consisting of polyoxyethylene derivatives, polyvinyl derivatives, copolymer of acrylic acid or ester, and copolymer of methacrylic acid or ester.

7. The tablet of claim 6 , wherein: a) the polysaccharide is inulin, pectin, algin derivative or agar; b) the polypeptide is casein or gelatin; c) the semi-synthetic polymers is a cellulose derivative; d) the polyoxyethylene derivative is polyethylene glycol; or e) the polyvinyl derivative is polyvinyl alcohol, polyvinylpyrrolidone or polystyrene sulfonate.

8. The tablet of claim 7 , wherein the cellulose derivative is methylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl ethylcellulose, hydroxypropyl ethylcellulose, hydroxypropyl methylcellulose phthalate or carboxymethylcellulose.

9. The tablet of claim 4 , wherein the release rate modifier is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropylcellulose, poly(ethylene oxide), cellulose acetate butyrate, cellulose acetate propionate, cellulose propionate, carrageenan, cellulose acetate, cellulose nitrate, methylcellulose, hydroxyethyl cellulose, ethylcellulose, polyvinyl acetate, latex dispersions, acacia, tragacanth, guar gum, gelatin, wax, and a combination thereof.

10. The tablet of claim 1 , wherein the membrane is a semipermeable membrane, a microporous membrane, or an impermeable membrane.

11. The tablet of claim 1 , wherein the tablet comprises three different drugs.

12. The tablet of claim 11 , wherein a drug in the first compressed composition is different than a drug in the second compressed composition.

13. The tablet of claim 12 , wherein a drug in the first compressed composition is different than a drug in the drug-containing core.

14. The tablet of claim 12 , wherein the drug in the second compressed composition is different than the drug in the drug-containing core.

15. The tablet of claim 11 , wherein the drug in the first compressed composition is the same as the drug in the drug-containing core.

16. The tablet of claim 11 , wherein the first compressed composition comprises two different drugs, the core comprises the third different drug, and the second compressed composition comprises a charge of either one of the three different drugs.

17. The tablet of claim 11 , wherein the first compressed composition comprises a charge of each of two different drugs, the core comprises a charge of the third different drug, and the second compressed composition comprises an additional charge of either one of the three different drugs.

18. The tablet of claim 11 , wherein the drug in the first compressed composition is the same as the drug in the second compressed composition.

19. The tablet of claim 18 , wherein the drug in the first compressed composition is the same as the drug in the drug-containing core.

20. The tablet of claim 18 , wherein the drug in the second compressed composition is different than the drug in the drug-containing core.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2021
From: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KORLÁTOLT FELELOSSÉGU TÁRSASÁG
To: ACELLA HOLDINGS, LLC
Reel/Frame 057627/0758 →
RELEASE OF SECURITY INTEREST Recorded Aug 28, 2021
From: CIT BANK, N.A., AS COLLATERAL AGENT
To: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KORLÁTOLT FELELOSSÉGU TÁRSASÁG
Reel/Frame 057319/0873 →
SECURITY INTEREST Recorded Aug 27, 2021
From: AVION PHARMACEUTICALS, LLC; SOVEREIGN PHARMACEUTICALS, LLC; ACELLA HOLDINGS, LLC
To: CIBC BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 057310/0385 →
CHANGE OF ADDRESS FOR ASSIGNEE Recorded Jul 2, 2020
From: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KFT
To: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KFT
Reel/Frame 053122/0081 →
SECURITY INTEREST Recorded Feb 3, 2016
From: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KORLÁTOLT FELELOSSÉGU TÁRSASÁG
To: CIT BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 037656/0777 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2014
From: TONEGUZZO, FERNANDO G.; MEYER, GLENN A.; RICCI, MARCELO A.; COPPARI, MARCELO A.; PASTINI, ANA C.; FISCHBEIN, GUSTAVO A.
To: OSMOTICA COSTA RICA SOCIEDAD AUTONIMA
Reel/Frame 033175/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2014
From: OSMOTICA CORP.
To: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KFT
Reel/Frame 033175/0317 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2014
From: OSMOTICA COSTA RICA SOCIEDAD AUTONIMA
To: OSMOTICA CORP.
Reel/Frame 033227/0577 →